Pharmacokinetics and Metabolism of 4‐O‐Methylhonokiol in Rats

The purpose of this study was to characterize the pharmacokinetics and metabolism of 4‐O‐methylhonokiol in rats. The absorption and disposition of 4‐O‐methylhonokiol were investigated in male Sprague–Dawley rats following a single intravenous (2 mg/kg) or oral (10 mg/kg) dose. Its metabolism was studied in vitro using rat liver microsomes and cytosol. 4‐O‐Methylhonokiol exhibited a high systemic plasma clearance and a large volume of distribution. The oral dose gave a peak plasma concentration of 24.1±3.3 ng/mL at 2.9±1.9 h and a low estimated bioavailability. 4‐O‐Methylhonokiol was rapidly metabolized and converted at least in part to honokiol in a concentration‐dependent manner by cytochrome P450 in rat liver microsomes, predicting a high systemic clearance consistent with the pharmacokinetic results. It was also shown to be metabolized by glucuronidation and sulfation in rat liver microsomes and cytosol, respectively. 4‐O‐Methylhonokiol showed a moderate permeability with no apparent vectorial transport across Caco‐2 cells, suggesting that intestinal permeation process is not likely to limit its oral absorption. Taken together, these results suggest that the rapid hepatic metabolism of 4‐O‐methylhonokiol could be the major reason for its high systemic clearance and low oral bioavailability. Copyright © 2013 John Wiley & Sons, Ltd.     

Phenolic‐Linked Biochemical Rationale for the Anti‐Diabetic Properties of Swertia chirayita (Roxb. ex Flem.) Karst.

The crude extract of Swertia chirayita, an important medicinal plant of Nepal, is locally used for many diseases including type 2 diabetes. In this study, crude aqueous and 12% ethanol solution extracts of S. chirayita collected from nine districts of Nepal were analyzed for anti‐diabetic‐linked anti‐hyperglycemia potential using in vitro biochemical assays. There was moderate‐to‐high positive correlation between antioxidant activity and total phenolic content of both extracts and moderate‐to‐high α‐glucosidase inhibitory activity. Although the anti‐diabetic property of S. chirayita is mainly attributed to the phytochemical swerchirin present in its hexane fraction, we propose that the crude extract of this plant used in local healing also has anti‐hyperglycemia potential. The crude extracts indicated the presence of three main phytochemicals mainly mangiferin, swertiamarin, and amarogentin and their derivatives. Among the standard compounds (mangiferin, swertiamarin, and amarogentin), mangiferin showed α‐glucosidase and 2,2‐diphenyl‐1‐picrylhydrazyl radical inhibitory activity indicating anti‐hyperglycemia potential. Copyright © 2012 John Wiley & Sons, Ltd.     

芒果甙保护柔红霉素致大鼠心肌细胞毒性中铁代谢的改变

目的:探讨铁代谢在芒果甙保护柔红霉素致大鼠心肌毒性细胞中的改变,并对其作用机制进行初步研究。方法:以4μmol/L柔红霉素单用或联合应用25～200μmol/L芒果甙为处理因素作用于大鼠心肌细胞24小时、48小时及72小时,应用qRT-PCR法检测各组心肌细胞铁调节蛋白1(IRP1)、铁调节蛋白2(IRP2)mRNA表达,应用RT-PCR法检测铁蛋白(Fn)mRNA表达,同时采用免疫细胞化学染色法检测转铁蛋白(Tf)及转铁蛋白受体(TfR)表达。结果:25～200μmol/L芒果甙模型组在干预24小时后IRP1、IRP2表达水平较柔红霉素(4μmol/L)组降低,干预48小时、72小时后,二者表达较柔红霉素组升高;干预24小时、72小时25～200μmol/L芒果甙模型组Fn表达较柔红霉素组随浓度升高逐渐降低,干预48小时后则较柔红霉素组均升高;柔红霉素组及25～200μmol/L芒果甙模型组24小时的Tf、TfR表达均明显高于空白对照组;72小时柔红霉素组的TfR表达明显低于空白对照组,而25～200μmol/L芒果甙模型组表达较柔红霉素组升高。结论:芒果甙能改变柔红霉素心肌毒性细胞的铁代谢水平,由此可推测,铁代谢可能是芒果甙保护柔红霉素致大鼠心肌细胞毒性的机制之一。     

非洛地平-美托洛尔复方透皮贴剂的制备及其在兔体内药动学研究

 目的制备非洛地平-美托洛尔复方透皮贴剂,研究其经家兔皮肤给药的药动学。方法健康新西兰白兔6只,3剂量3周期随机交叉单次给予低、中、高3种不同剂量的非洛地平-美托洛尔复方透皮贴剂,其中非洛地平/美托洛尔剂量分别为:1/10,3/30,9/90 mg·kg^-1/mg·kg^-1,剂间间隔为2周,给药时间为48 h。分别于给药后60 h内多点取静脉血;用气相色谱-电子捕获法分别测定血浆中非洛地平和美托洛尔的浓度。用DAS软件计算药动学参数并评价不同剂量组间的参数差异和贴剂的体内作用特征。结果贴剂缓释特征明显,血药浓度稳定持久。经皮给药后低、中、高3种剂量组间非洛地平和美托洛尔的ρ_max、AUC_0→60和AUC_0→∞均有显著性差异(P<0.05),且ρ_max和AUC_0→∞均与剂量(D)呈良好的线性关系(P<0.05),非洛地平的回归方程为ρ_max=6.634 2D+4.355(r²=0.993 8)和AUC_0→∞=295.08D+92.322(r²=0.992 6),美托洛尔的回归方程为ρ_max=8.462 8D+51.528(r²=0.991 4)和AUC_0→∞=315.14D+1 474.8(r²=0.998 7);两药的t_max,MAT,MRT_0→60和MRT_0→∞均无显著性差异(P>0.05),t_max均较长,分别为(21.50±8.14)～(27.00±12.30)h和(25.33±14.40)～(37.50±9.99)h,MRT_0→∞均较长且相近,分别为(28.48±2.71)～(31.80±0.85)h和(28.09±4.41)～(31.79±1.29)h。结论非洛地平-美托洛尔复方透皮贴剂缓释长效的药动学特征明确而稳定,达到了预期较长时间维持平稳有效血药浓度、提高药物生物利用度、减少服药频次、降低毒副作用的设计目的。     

黄芩苷在家兔感染性脑水肿模型中的药代动力学研究

 目的：研究黄芩苷在家兔获得脑水肿前后,体内药代动力学参数的变化。方法：18只家兔随机分为两组,一组感染百日咳菌液获得脑水肿模型,另一组为正常对照组,静脉注射60mg/kg黄芩甙,于注射后不同时间内抽取血样,采用高效液相色谱法测定,黄芩甙血药浓度测定值用3P87程序包进行拟合。结果：静脉注射黄芩甙后,在家兔体内代谢符合二室开放模型。对照组与脑水肿模型组的主要药动力学参数：t_1/2α分别为0.1196h和0.2158h;t_1/2β分别为2.381h和2.562h;V_d分别为1.006L·kg^-1和1.414L·kg^-1;CL分别为1.843L·h^-1·kg^-1和1.877L·h^-1·kg^-1。结论：用黄芩苷治疗脑水肿时,要考虑其药代动力学参数的变化。     

克班宁注射剂在家兔体内的药动学研究

目的：建立血清中克班宁(crebanine,Cre)浓度的高效液相测定方法,探讨克班宁注射剂在家兔体内的药动学过程。方法：家兔按2.0 mg·kg^-1量耳缘静脉注射克班宁后5,10,20,30,50,70,90,110 min采血,用HPLC测定血清中克班宁浓度,以DAS软件拟合药动学参数。结果：克班宁平均回收率分别为(89.4±2.5)%,(105.4±4.1)%,(102.7±5.8)%；精密度分别为日内RSD 2.8%,3.9%,5.6%；日间RSD分别为8.2%,6.8%,7.2%。克班宁注射剂在家兔体内成二室模型,雌、雄兔体内的药动学参数经t检验差异无显著性意义。主要药动学参数为：t_1/2α=(3.246±0.222) min,t_1/2β=(36.675±5.525) min,C_max=(1.401±0.063) mg·L^-1,V_d=(5.928±0.877) L·kg^-1,Cl=(0.051±0.003) L·min^-1·kg^-1。结论：克班宁静注在家兔体内为超速处置类(t_1/2<1 h)药物,其在体内的分布迅速、广泛。     

Effect of Wuzhi tablet (Schisandra sphenanthera extract) on the pharmacokinetics of paclitaxel in rats

Wuzhi tablet (WZ, registration no. in China: Z20025766) is a preparation of an ethanol herb extract of Wuweizi (Schisandra sphenanthera) containing 7.5 mg Schisantherin A per tablet. It was reported recently that WZ could significantly increase the blood concentrations of tacrolimus, which might be due to the inhibitory effect of WZ and its ingredients on P‐gp and/or CYP450 activity. Paclitaxel is a substrate of the efflux transporter P‐gp, and is mainly metabolized by CYP450 enzymes in the liver. Therefore, the purpose of this study was to investigate whether and how WZ affects the pharmacokinetics of paclitaxel in rats. After pretreatment with WZ, there were significant increases in the AUC_0‐24h of oral paclitaxel (from 280.8 ± 97.3 to 543.5 ± 115.2 h ng/mL; p < 0.05) and C_max (from 44.6 ± 16.4 to 86.8 ± 16.1 ng/mL; p < 0.05). The pharmacokinetic data for i.v. paclitaxel with WZ showed a relatively small (when compared against oral paclitaxel) but still significant increase in AUC_0‐24h (from 163.6 ± 22.1 to 212.7 ± 17.7 h ng/mL; p < 0.05) and a decrease in clearance (from 3.2 ± 0.6 to 2.2 ± 0.3 L/h/kg; p < 0.05). Thus, the presence of WZ improved the systemic exposure of paclitaxel in rats. The herb–drug interaction between WZ and paclitaxel should be taken into consideration in clinical use. Copyright © 2011 John Wiley & Sons, Ltd.     

基于制马钱子在大鼠体内药动学行为的蓄积可能性研究

目的研究临床剂量下制马钱子在大鼠体内多次给药的药动学过程及各组织脏器中的含量,探讨马钱子在体内蓄积的可能性。方法大鼠分别单次、多次ig给予制马钱子,采用UPLC-Q-Orbitrap HRMS法测定大鼠血浆和组织中马钱子碱和士的宁的血药浓度,比较不同给药次数下2种成分的药动学和组织分布差异,探讨其在体内是否存在蓄积。结果制马钱子单次给药后,马钱子碱和士的宁的主要药动学参数半衰期(t_(1/2))为10.59、8.39 h,达峰时间(t_(max))为0.77、0.64 h,t_(1/2Ka)为5.38、2.63 h,峰浓度(C_(max))为2.97、10.83 ng/L,药时曲线下面积(AUC_(0～t))为87.36、172.24 ng·h/L,药物消除率(CL/F)为40 637.08、38 370.26 L/(h·kg);制马钱子中马钱子碱与士的宁的血药浓度在大鼠给药3 d后达到稳态。末次给药后,制马钱子中马钱子碱和士的宁的主要药动学参数分别为:t_(1/2)为7.07、4.75 h,t_(max)为0.48、0.46 h,t_(1/2Ka)为3.23、1.09 h,C_(max)为5.77、34.83 ng/L,AUC_(0～t)为32.80、107.86 ng·h/L,CL/F为75 920.52、43 871.54 L/(h·kg)。与单次给药比较,马钱子碱和士的宁在多次给药后,肝、肾组织中的含量明显减少,其他组织无明显变化。结论制马钱子中马钱子碱与士的宁在大鼠体内单次、多次给药的药动学过程均符合一室模型,体内血药浓度变化过程趋势基本一致。两者在大鼠体内具有吸收速度快的药动学特征。给药3 d后,马钱子碱与士的宁血药浓度达到稳态,并未出现随着给药次数的增加,血药浓度持续增加的现象。单次和多次给药后的各组织含量并未增高。提示在安全给药剂量下,多次给予制马钱子,不会引起马钱子碱与士的宁在大鼠体内血药浓度的持续叠加升高,导致中毒现象的发生。     

健康人单次和多次口服阿立哌唑片的药动学研究

 目的建立测定阿立哌唑血浆药物浓度的HPLC-UV检测法,研究国产阿立哌唑片在人体的药动学。方法12名健康志愿受试者和14名健康志愿受试者分别单剂量和多剂量po 20 mg国产阿立哌唑片,采用HPLC测定给药后不同时间点血浆中阿立哌唑浓度,用DAS1.0(3P97药动学程序Windows升级版)处理经时血药浓度数据,计算主要药动学参数。结果单次口服阿立哌唑片后的主要药动学参数:ρ_max为(108.4±22.5)μg·L^-1,t_max为(4.9±0.7)h,AUC_{0～192 h}为(5 748.2±874.5)μg·h·L^-1,t_1/2β为(107.43±29.03)h,CL/F和V/F分别为(3.56±0.55)L·h^-1和(261.60±49.14)L。多次口服阿立哌唑片共14 d达稳态,稳态血药浓度期间给药后(4.0±0.9)h达到峰浓度(480.3±126.2)μg·L^-1,AUC_{0～360 h}为(38 166.6±13 241.2)μg·h·L^-1,t_1/2β为(91.0±21.1)h,CL/F和V/F分别为(0.62±0.36)L·h^-1和(60.9±43.7)L。结论国产阿立哌唑的血药浓度-时间曲线符合二室开放模型,为今后的合理用药打下基础。     

A pilot pharmacokinetic study of miroestrol and deoxymiroestrol on rabbit sera using polyclonal antibody‐based icELISA analysis

Miroestrol (ME) and deoxymiroestrol (DME) are the most potent phytoestrogens and bioactive markers in Pueraria candollei var. mirifica tuberous roots. To understand their pharmacokinetic profiles, a pharmacokinetic study of ME and DME, at 0.43 and 0.21 mg per kg body weight, respectively, in three rabbits was performed after orally administering a single dose of P. candollei var. mirifica enriched fraction extract. Two established polyclonal antibody‐based indirect competitive enzyme‐linked immunosorbent assays were validated to determine ME and DME in rabbit sera. In rabbits, the area under the 0‐ to 48‐hr concentration‐time curve of ME and DME were 854.92 and 1,692.84 ng·h/ml, respectively. The maximum concentration of ME was measured 1 hr after administration as 69.62 ± 8.28 ng/ml, and the maximum concentration of DME was measured at 3 hr as 81.8 ± 5.43 ng/ml. These results provide an initial approach for designing and studying the relationship between the ME and DME levels and their therapeutic effects based on their pharmacokinetic profiles.     

甲磺酸帕珠沙星对氨茶碱在兔体内药动学影响的研究

 目的研究甲磺酸帕珠沙星对兔体内氨茶碱药动学的影响。方法采用自身对照法,以HPLC测定兔单用氨茶碱及与甲磺酸帕珠沙星合用后的茶碱血清浓度,计算药动学参数。结果经BAPP2.3药动程序拟合,甲磺酸帕珠沙星使兔血清中茶碱的曲线下面积AUC由152.0mg·h·L^-1增加到361.4mg·h·L^-1;半衰期t_1/2由2.292h延长至6.823h;MRT由4.944h延长到9.383h,均有非常显著性差异(P<0.01)。结论家兔体内合用甲磺酸帕珠沙星对氨茶碱的消除药动学有显著抑制作用。     

Pharmacokinetic Effects of Baicalin on Cerebral Ischemia-reperfusion after iv Administration in Rats

Objective To investigate the pharmacokinetic effects of baicalin on cerebral ischemia-reperfusion (I/R) after iv administration in rats. Methods The cerebral I/R rats were induced by occluding the bilateral carotid arteries of normal rats for 2 h, followed by reperfusion. The resultant animals were immediately iv administrated with baicalin (90 mg/kg), whilst the same dose of baicalin was injected to the normal rats. Plasma samples were collected at different time to construct pharmacokinetic profiles by plotting drug concentration vs time. Quantification of baicalin in rat plasma was achieved using a simple and rapid HPLC method. Results In normal rats, the major parameters of distribution half-life, elimination half-life, area under the plasma concentration-time (AUC), apparent volume of distribution (Vd), and clearance (CL), estimated by an open two-compartmental model, were 0.8868 min, 26.0968 min, 149.6204 mg/min·L, 4.765 L/kg, and 0.5776 L/ kg·min), respectively. However, in I/R rats, the corresponding parameters were 2.084 min, 34.4998 min, 260.0188 μg·min/L, 5.9376 L/kg, and 0.334 L/(kg·min), respectively. Conclusion The cerebral I/R could significantly increase AUC and Vd values, decrease CL values, and prolong the terminal half-life of baicalin. These findings suggest that the injuries of I/R could play an important role in pharmacokinetic process of baicalin.     

Pharmacokinetic Herb–Drug Interaction between Essential Oil of Aniseed (Pimpinella anisum L., Apiaceae) and Acetaminophen and Caffeine: A Potential Risk for Clinical Practice

Aniseed (Pimpinella anisum L., Apiaceae) and its essential oil (EO) have been widely used. Because there are some data about the impact of aniseed EO on drug effects, this survey aimed to assess the potential of pharmacokinetic herb–drug interaction between aniseed EO and acetaminophen and caffeine in mice. The chemical analysis (gas chromatography–mass spectrometry) of aniseed EO has confirmed trans‐anethole (87.96%) as the main component. The pharmacokinetic studies of intraperitoneally (i.p.) and orally applied acetaminophen (200 mg/kg) and caffeine (20 mg/kg) were performed in mice after 5 days of oral treatment with human equivalent dose of aniseed EO (0.3 mg/kg/day). The analysis of pharmacokinetic data showed that in the group treated by aniseed EO, the significant decrease in the peak plasma concentration of acetaminophen after oral application (p = 0.024) was revealed when compared with control group and the reduction of systemic exposure to the drug after oral application (74 ± 32% vs. 85 ± 35% in the control) was noted. The bioavailability of orally applied caffeine was also significantly decreased (p = 0.022) after the EO treatment in comparison with the control (57 ± 24% vs. 101 ± 29%). Therefore, the compromised therapeutic efficacy of acetaminophen and caffeine during the usage of aniseed EO preparations should be considered. Copyright © 2015 John Wiley & Sons, Ltd.     

载顺铂磁性纳米药物药动学研究

 目的 高效液相色谱法（HPLC）测定血浆中顺铂（DDP）含量,研究载顺铂磁性纳米药物在家兔体内的药动学特征及其相关药动学参数。方法 家兔12 只,随机分为2 组。分别于兔耳缘静脉注射3 mg·kg-1（按DDP含量计）剂量载顺铂磁性纳米药物和DDP,按设定时间于对侧耳缘动脉采血,通过改良HPLC法测定血浆中DDP浓度。以3P97药动学程序处理血浆药物浓度-时间数据,进行药动学分析。结果 本实验单剂量静注DDP在家兔体内的药动学特征符合二室模型,载顺铂磁性纳米药物则符合三室模型。主要动力学参数与DDP相比,载顺铂磁性纳米药物的清除率（CL）是DDP的0.620倍,t1/2α是DDP的1.579倍,t1/2β是DDP的0.552倍,V_d是DDP的1.845倍,血药浓度-时间曲线下面积（AUC ）是DDP的1.237倍。结论 实验结果表明,载顺铂磁性纳米药物经改良,提高了药物的稳定性,载顺铂磁性纳米药物改变了DDP的药动学特性。药动学参数表明,药物通过生物转化或排泄从体内消除加快,组织对药物的摄取量增加。     

腹膜透析对邻异丙基苯基甲基氨基甲酸酯毒物动力学的影响

 目的：对新型农药邻异丙基苯基甲基氨基甲酸酯(叶蝉散，IPMC)在家兔体内的代谢动力学、毒效应及腹膜透析进行研究，为临床救治此类农药中毒病人时提供理论依据。方法：对于ig 50 mg/kg IPMC染毒后的家兔在规定时间内采血，腹膜透析组采血同时收集腹膜透析液，用HPLC测定血清及腹膜透析液中IPMC的浓度，用3P87药物动力学程序计算动力学参数，并对腹膜透析组与非透析组的各项动力参数及其毒效进行比较。结果：IPMC 50 mg/kg ig后，兔体内的动力学过程符合一级吸收一室模型，生物半衰期(T_1/2)为29.01±6.5 min,腹膜透析能显著降低血中IPMC的浓度，透析组与非透析组相比，血清中IPMC的浓度-时间曲线下面积(AUC)明显减小(P＜0.05),且所有受试动物的中毒症状减轻，腹膜透析平均清除率为29.49±13.6 ml/min。结论：家兔ig IPMC中毒时，体内的代谢符合线性动力学过程，其代谢半衰期短，清除较快，且腹膜透析可以加速本品的清除。     

Hypoglycaemic activity of Anthocleista vogelii (Planch) aqueous extract in rodents

The hypoglycaemic effect of Anthocleista vogelii was studied in mice, rats and rabbits. Aqueous extract of the plant obtained by infusion from finely pulverized root was used. The extract (100, 400 and 800 mg/kg) induced significant hypoglycaemic activity in a dose-related fashion at 2 h after oral administration in mice and rats with ED₂₅ of 250 mg/kg and 350 mg/kg respectively. The extract (800 mg/kg, orally) similarly induced statistically significant lowering of blood glucose levels at 8 h in normoglycaemic rabbits. The extract (400 mg/kg and 800 mg/kg, orally) also caused reduction of blood glucose levels in alloxan-induced diabetic animals. The results of this study indicate that the aqueous extract of the roots of Anthocleista vogelii possess favourable hypoglycaemic activity both in normo and hyperglycaemic animals compared to chlorpropamide as a standard.     

Mechanism of protective action of mangiferin on suppression of inflammatory response and lysosomal instability in rat model of myocardial infarction

Lysosomal instability has been suggested as a major factor in the development of cellular injury during myocardial necrosis through the formation of inflammatory mediators. The present study was designed to investigate the effect of mangiferin on lysosomal hydrolases and TNF‐α production during isoproterenol (ISPH) induced myocardial necrosis in rats. The rats given ISPH (200 mg/kg body weight twice, subcutaneous) for 2 days showed a significant increase in plasma TNF‐α production, serum and heart lysosomal hydrolases activity. ISPH administration to rats resulted in decreased stability of the membranes, which was reflected by the lowered activity of cathepsin‐D and β‐glucuronidase in mitochondrial, nuclear, lysosomal and microsomal fractions. Pretreatment with mangiferin (100 mg/kg body weight, intraperitoneally) for 28 days, significantly prevented the alterations and restored the enzyme activities to near‐normal status. These findings demonstrate that mangiferin could preserve lysosomal integrity through decrease in the inflammatory process and hence establish the cardioprotective effect of mangiferin. Copyright © 2009 John Wiley & Sons, Ltd.     

甜茶素在大鼠体内的代谢产物鉴定与药动学研究

目的对甜茶素在大鼠体内的代谢产物进行定性分析,并考察甜茶素在大鼠体内的药动学特征。方法 SD大鼠ig甜茶素(125mg/kg),收集不同时间段的尿液、粪便、胆汁和血浆。采用超高效液相色谱-四级杆飞行时间质谱联用技术(UPLC-Q-TOF-MS/MS)分析其在大鼠体内的代谢产物;基于超高效液相色谱串联质谱(UPLC-MS/MS)建立一种测定大鼠血浆中甜茶素含量的方法,初步研究甜茶素的药动学特征。结果大鼠ig甜茶素后,在尿液、粪便、胆汁和血浆中共检测并初步鉴定了1种原型成分和58种代谢物,主要代谢途径有脱氢化、羟基化、去葡萄糖基化、葡萄糖醛酸化、硫酸酯化等。甜茶素在大鼠体内的吸收较快,在0.12 h血药浓度达到最大值,半衰期为4.20 h,较大的表观分布容积提示甜茶素可能存在一定的组织分布。结论甜茶素在大鼠体内吸收迅速,并经历广泛的代谢反应,为进一步阐明甜茶素药效物质基础提供依据。     

阿魏酸在微循环障碍（血瘀证）兔体内的药代动力学

以ＲＰ—ＨＰＬＣ法同时测定了阿魏酸在正常及高分子右旋糖酐所致微循环障碍（血瘀证）兔体内经时浓度，以ＭＣＰＫＰ药动学程序在ＣＯＭＰＡＱ８０３８６机上自动拟合了药动学参数，结果表明，与正常组相比，阿魏酸在微循环障碍（血瘀证）兔体内的分布容积（Ｖ１和ＶＢ）及消除速率（ＣＬＢ）显著减小（Ｐ＜０．０５），半衰期（ｔ１／２Ｂ）及相同时间段曲线下面积（ＡＵＣ）非常显著增加（Ｐ＜０．０１）。     

不同稳定剂修饰的槲皮素纳米晶在大鼠体内注射药动学及组织分布研究

目的 以普朗尼克F68(F68)、普朗尼克F127(F127)、甘草酸（glycyrrhizinic acid,GL）、维生素E聚乙二醇琥珀酸酯（TPGS）为稳定剂制备槲皮素纳米晶（quercetin nanocrystals,QT-NCs）,探讨不同稳定剂种类对QT-NCs注射药动学及组织分布的影响。方法 采用HPLC法测定大鼠血浆和组织中的槲皮素质量浓度,并用DAS 2.0软件计算其药动学参数,进行比较。结果 药动学结果显示,AUC0～t呈如下顺序：QT-NCs/GL[(464.87±100.51)mg·L/h]>QT-NCs/TPGS[(339.82±73.82)mg·L/h]>QT-NCs/F68[(293.00±44.72)mg·L/h]>QT-NCs/F127[(245.01±28.72)mg·L/h]。组织分布研究结果显示,不同稳定剂修饰的QT-NCs具有不同的组织分布行为,肝脏的AUC0～t顺序与血浆AUC0～t一致。此外,QT-NCs/GL在肝、脾、肺的分布最高（P<0.01）。结论 稳定剂种类可以影响QT-NCs的注射药动学及组织分布。